← Jazz Pharmaceuticals plc
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $1.5b |
$1.6b
+8.79%
|
$1.9b
+16.82%
|
$2.2b
+14.32%
|
$2.4b
+9.34%
|
$3.1b
+30.91%
|
$3.7b
+18.26%
|
$3.8b
+4.78%
|
$4.1b
+6.12%
|
$4.3b
+4.88%
|
$4.6b
+7.82%
|
|
| Research and Development Expense | $162.3m | $198.4m | $226.6m | $299.7m | — | — | — | — | — | — | $815.6m | |
| Selling, General and Administrative Expense | $502.9m | $544.2m | $683.5m | $736.9m | $854.2m | $1.5b | $1.4b | $1.3b | $1.4b | $1.8b | $1.7b | |
| Amortization of Intangible Assets | $102.0m | $152.1m | $201.5m | $354.8m | $259.6m | $525.8m | $599.2m | $608.3m | $627.3m | $654.7m | — | |
| Operating Expenses | $896.3m | $1.1b | $1.3b | — | — | — | — | — | — | — | $3.6b | |
| Operating Income (Loss) | $591.7m |
$528.8m
-10.62%
|
$614.8m
+16.26%
|
$532.4m
-13.41%
|
$378.1m
-28.98%
|
$170.3m
-54.96%
|
($65.5m)
-138.48%
|
$578.6m
+982.95%
|
$716.6m
+23.86%
|
($430.2m)
-160.04%
|
$1.0b
+336.22%
|
|
| Interest Expense, Debt | — | $37.8m | $56.7m | $59.1m | $76.1m | $89.9m | $32.8m | $32.8m | — | — | $171.0m | |
| Foreign Currency Transaction Gain (Loss), before Tax | $3.4m | ($10.0m) | ($6.9m) | ($5.8m) | ($3.3m) | ($4.3m) | ($19.0m) | $8.8m | ($8.2m) | ($2.6m) | — | |
| Income (Loss) from Equity Method Investments | ($379k) | ($1.0m) | ($2.2m) | ($4.1m) | ($3.0m) | ($714k) | ($9.9m) | ($3.0m) | ($1.7m) | ($732k) | — | |
| Interest Income (Expense), Nonoperating, Net | ($61.9m) | ($77.8m) | ($77.1m) | ($72.3m) | ($99.7m) | ($278.8m) | ($288.2m) | ($289.4m) | ($238.1m) | ($195.1m) | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $179.6m | $77.5m | $170.7m | ($6.5m) | ($102.3m) | $97.6m | ($50.3m) | $449.2m | $497.9m | $164.7m | $727.7m | |
| Current Income Tax Expense (Benefit) | $176.4m | $177.9m | $169.0m | $163.5m | $170.5m | $146.9m | $133.6m | $140.3m | $116.9m | $172.5m | ($213.2m) | |
| Income Tax Expense (Benefit) | $135.2m | ($47.7m) | $80.2m | ($73.2m) | $33.5m | $216.1m | ($158.6m) | ($119.9m) | ($91.4m) | ($272.4m) | ($213.2m) | |
| Net Income (Loss) Attributable to Parent | $396.8m |
$487.8m
+22.94%
|
$447.1m
-8.35%
|
$523.4m
+17.06%
|
$238.6m
-54.41%
|
($329.7m)
-238.16%
|
($224.1m)
+32.03%
|
$414.8m
+285.14%
|
$560.1m
+35.02%
|
($356.1m)
-163.58%
|
$940.8m
+364.15%
|
|
| Net Income (Loss) Attributable to Noncontrolling Interest | $0 | $0 | — | — | — | — | — | — | — | — | $940.8m | |
| Earnings Per Share, Basic | $6.56 | $8.13 | $7.45 | $9.22 | $4.28 | ($5.52) | ($3.58) | $6.55 | $9.06 | ($5.84) | $15.21 | |
| Earnings Per Share, Diluted | $6.41 | $7.96 | $7.30 | $9.09 | $4.22 | ($5.52) | ($3.58) | $6.10 | $8.65 | ($5.84) | $14.61 | |
| Weighted Average Number of Shares Outstanding, Basic | 60.5m | 60.0m | 60.0m | 56.7m | 55.7m | 59.7m | 62.5m | 63.3m | 61.8m | 61.0m | 61.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | 61.9m | 61.3m | 61.2m | 57.5m | 56.5m | 59.7m | 62.5m | 72.1m | 66.0m | 61.0m | 64.3m | |
| Additional Financial Items | ||||||||||||
| Costs and Expenses | — | — | — | $1.6b | $2.0b | $2.9b | $3.7b | $3.3b | $3.4b | $4.7b | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.